News

Public · Published

China's WuXi AppTec nine-month revenue rises on chemistry segment growth; lifts 2026 outlook

WuXi AppTec's nine-month revenue rose 39% year-over-year, helped by growth in its chemistry segment. The company raised its 2026 revenue guidance to RMB61.0-61.9 bln from RMB58.5-60.5 bln and lifted its 2026 adjusted free cash flow forecast.

Published:

Updated:

What happened

WuXi AppTec's nine-month revenue rose 39% year-over-year, helped by growth in its chemistry segment. The company raised its 2026 revenue guidance to RMB61.0-61.9 bln from RMB58.5-60.5 bln and lifted its 2026 adjusted free cash flow forecast.

Confirmed

Global impact / market context

Higher revenue and a raised outlook suggest demand for WuXi's drug research services is strong. More cash available, which means money left after running and investing in the business, could fund new capacity and support future growth without relying heavily on borrowed money.

Analyst inference

Analysts currently rate the shares a buy, with a median 12-month price target of CNY185.25, about 26.9% above the last price shown. That implies investors expect continued growth, so any slowdown in chemistry or TIDES orders could challenge those expectations.

Analyst inference

What to watch

  1. Watch whether WuXi Chemistry keeps growing through pipeline progression to late stages and the ramp-up of new capacity, since the company named these as drivers of the segment's strong growth. Confirmed
  2. Track the TIDES business, which covers newer drug types, because the company said increased customer and molecule counts supported rapid growth there; slower customer additions could weaken revenue. Proposed
  3. Monitor adjusted free cash flow against the raised RMB14.5-15.5 bln forecast, because falling short could limit capital spending on new capacity and pressure the shares' premium rating. Analyst inference

Evidence

  • Original source link unavailable